Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
REINFORCED REGIMEN OF INTERFERON ALPHA-2A REDUCES THE INCIDENCE OF CIRRHOSIS IN PATIENTS WITH CHRONIC HEPATITIS-C - A MULTICENTER RANDOMIZED TRIAL
Autore:
DEGOS F; DAURAT V; CHEVRET S; GAYNO S; BASTIE A; RIACHI G; BATOLOMEIPORTAL I; BARANGE K; MOUSSALLI J; NAVEAU S; BAILLY F; CHAUMETRIFFAUD P; CHASTANG C;
Indirizzi:
HOP BEAUJON,SERV HEPATOGASTROENTEROL 2,100 BVD GEN LECLERC F-92110 CLICHY FRANCE HOP BEAUJON,SERV HEPATOGASTROENTEROL CLICHY FRANCE ASSISTANCE PUBL HOP PARIS,GERMED,DELEGAT RECH CLIN PARIS FRANCE HOP ST LOUIS,DEPT BIOSTAT & MED INFORMAT PARIS FRANCE HOP RENE DUBOS,SERV HEPATOGASTROENTEROL PONTOISE FRANCE HOP HENRI MONDOR,SERV HEPATOGASTROENTEROL F-94010 CRETEIL FRANCE HOP CHARLES NICOLLE,GRP RECH APPAREIL DIGESTIF F-76031 ROUEN FRANCE HOP LA CONCEPT,SERV HEPATOGASTROENTEROL MARSEILLE FRANCE HOP PURPAN,SERV HEPATOGASTROENTEROL TOULOUSE FRANCE HOP LA PITIE SALPETRIERE,SERV HEPATOGASTROENTEROL PARIS FRANCE HOP ANTOINE BECLERE,SERV HEPATOGASTROENTEROL LYON FRANCE HOP HOTEL DIEU,SERV HEPATOGASTROENTEROL LYON FB FRANCE
Titolo Testata:
Journal of hepatology
fascicolo: 2, volume: 29, anno: 1998,
pagine: 224 - 232
SICI:
0168-8278(1998)29:2<224:RROIAR>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
NON-B-HEPATITIS; CHRONIC NON-A; THERAPY; ALPHA; METAANALYSIS; INFECTION; EFFICACY; DURATION;
Keywords:
CHRONIC HEPATITIS; INTERFERON-ALPHA; RANDOMIZED TRIAL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
31
Recensione:
Indirizzi per estratti:
Citazione:
F. Degos et al., "REINFORCED REGIMEN OF INTERFERON ALPHA-2A REDUCES THE INCIDENCE OF CIRRHOSIS IN PATIENTS WITH CHRONIC HEPATITIS-C - A MULTICENTER RANDOMIZED TRIAL", Journal of hepatology, 29(2), 1998, pp. 224-232

Abstract

Background/Aims: Our aim was to assess and compare the long-term effect of interferon at standard (6 months) and reinforced dose and duration regimens in chronic hepatitis C. Methods: A multicentre institutional trial included 244 previously untreated patients with chronic hepatitis C, without cirrhosis, who were randomly allocated to either standard (3 MU thrice a meek for 24 weeks; n=120) or reinforced (6 MU dailyfor 12 days, 6 MU thrice a week for 22 weeks, 3 MU thrice a week for 24 weeks; n=124) regimens. The main endpoint was sustained ALT response at 72 weeks (18 months); secondary end-points mere virological (branched DNA and PCR) and histological responses (incidence of cirrhosis) at month 18. Results: Sustained ALT response was observed in five patients (4%, 95% confidence interval 0-8%) in the standard group and in 21 patients (18%, 95% confidence interval 11-25%), from the reinforced group (p=0.002), in agreement with virological response in 21 (81%) patients. Cirrhosis at month 18 was observed in ten (10%) patients in the standard group and one (1%) in the reinforced group (p=0.004). Conclusions: The standard regimen of interferon, in chronic hepatitis C, confers a minimal sustained response rate at 18 months and may not prevent the occurrence of cirrhosis. Reinforced regimens allow sustained response to be reached in a limited number of patients and reduce the risk of cirrhosis during 18 months of follow-up.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 06:08:12